bavituximab
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans. — Wikipedia
Clinical trial activity
27 trials · 27 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2005 (NCT00129337)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2/Phase 3
- Breast Neoplasms, Male · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 2
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Hepacivirus · Phase 1
- Hepatitis C · Phase 1/Phase 2
- HIV Infections · Phase 1
- Liver Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- PhosphatidylserineINHIBITOR
Phosphatidylserine inhibitor
In most tissues, the principal target of bavituximab, phosphatidylserine (PS), is restricted to the internal surface of the cell membrane. Bavituximab binds a complex of beta2 glycoprotein 1 (beta2GP1) and PS, triggering antitumor effects via a number of mechanisms. Principally, bavituximab acts as a vascular targeting agent. The bavituximab¿beta2GP1¿PS complex induces host effector processes such as antibody-dependent cellular cytotoxicity, resulting in vascular destruction.
- PhosphatidylserineImmunity, passive
Phosphatidylserine immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBavituximab ↗
- ChEMBLCHEMBL1742989 ↗
Also known as
- bavituximab
- bavituximab
- bavituximab
- bavituximab plus paclitaxel
- ch3g4
- tarvacin
- tarvacin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05249569 | Phase 2 | Nov 4, 2022 | Pfizer, The University of Texas, Dallas |
| NCT04150900 | Phase 2 | Jan 1, 2020 | University of Maryland |
| NCT04099641 | Phase 2 | Sep 11, 2019 | Merck, Oncologie Inc. |
| NCT03519997 | Phase 2 | Apr 26, 2018 | Merck, The University of Texas, Dallas |
| NCT03139916 | Phase 2 | Jun 30, 2017 | Avid Bioservices, Harvard University, National Comprehensive Cancer Network |
| NCT02989870 | Phase 1 | Mar 27, 2017 | National Comprehensive Cancer Network, University of South Florida |
| NCT02685306 | Phase 2 | Mar 1, 2016 | Avid Bioservices, Providence Health & Services |
| NCT02673814 | Phase 2 | Feb 1, 2016 | Avid Bioservices |
| NCT02651610 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2015 | Avid Bioservices, Indiana University |
| NCT01984255 | Phase 1 | Apr 1, 2014 | The University of Texas, Dallas |
| NCT01999673 | Phase 3 | Dec 1, 2013 | Avid Bioservices |
| NCT01634685 | Phase 1 | Aug 1, 2012 | The University of Texas, Dallas |
| NCT01335204 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Avid Bioservices, Medical University of South Carolina, University of South Carolina |
| NCT01323062 | Phase 1 | May 1, 2011 | Avid Bioservices, University of North Carolina at Chapel Hill |
| NCT01288261 | Phase 1 | Jan 1, 2011 | National Cancer Institute (NCI), University of Arizona |
| NCT01273948 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | Avid Bioservices |
| NCT01272791 | Phase 2 | Jan 1, 2011 | Avid Bioservices |
| NCT01264705 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | The University of Texas, Dallas |
| NCT01138163 | Phase 2 | Jun 1, 2010 | Avid Bioservices |
| NCT01160601 | Phase 2 | Jun 1, 2010 | Avid Bioservices |
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avid Bioservices | For profit | 18 | 15 | 3 | 2005 |
| The University of Texas, Dallas | Academic/Hospital | 6 | 5 | 2 | 2005 |
| Merck | For profit | 2 | 0 | 1 | 2018 |
| National Comprehensive Cancer Network | Academic/Hospital | 2 | 0 | 2 | 2017 |
| University of Arizona | Academic/Hospital | 2 | 1 | 1 | 2005 |
| AIDS Research Consortium of Atlanta | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Alamo Medical Research | For profit | 1 | 0 | 1 | 2006 |
| Bach & Godofsky, MD, PA | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Impact Clinical Trials | For profit | 1 | 0 | 1 | 2007 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| Oncologie Inc. | For profit | 1 | 1 | 1 | 2019 |
| Orange Coast Medical Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Pfizer | For profit | 1 | 0 | 1 | 2022 |
| Premiere Oncology | For profit | 1 | 0 | 1 | 2005 |
| Providence Health & Services | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Texas A&M University | Academic/Hospital | 1 | 0 | 1 | 2005 |